Treatment of Hilar Cholangiocarcinoma (Klatskin Tumors) with Hepatic Resection or Transplantation
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 187 (4) , 358-364
- https://doi.org/10.1016/s1072-7515(98)00207-5
Abstract
Background: Because of the rarity of hilar cholangiocarcinoma, its prognostic risk factors have not been sufficiently analyzed. This retrospective study was undertaken to evaluate various pathologic risk factors which influenced survival after curative hepatic resection or transplantation. Methods: Between 1981 and 1996, 72 patients (43 males and 29 females) with hilar cholangiocarcinoma underwent hepatic resection (34 patients) or transplantation (38 patients) with curative intent. Medical records and pathologic specimens were reviewed to examine the various prognostic risk factors. Survival was calculated by the method of Kaplan-Meier using the log rank test with adjustment for the type of operation. Survival statistics were calculated first for each kind of treatment separately, and then combined for the calculation of the final significance value. Results: Survival rates for 1, 3, and 5 years after hepatic resection were 74%, 34%, and 9%, respectively, and those after transplantation were 60%, 32%, and 25%, respectively. Univariate analysis revealed that T-3, positive lymph nodes, positive surgical margins, and pTNM stage III and IV were statistically significant poor prognostic factors. Multivariate analysis revealed that pTNM stage 0, I, and II, negative lymph node, and negative surgical margins were statistically significant good prognostic factors. mFor the patients in pTNM stage 0–II with negative surgical margins, 1-, 3-, and 5-year survivals were 80%, 73%, and 73%, respectively. For patients in pTNM stage IV-A with negative lymph nodes and surgical margins, 1-, 3-, and 5-year survivals were 66%, 37%, and 37%, respectively. Conclusions: Satisfactory longterm survivals can be obtained by curative surgery for hilar cholangiocarcinoma either with hepatic resection or liver transplantation. Redefining pTNM stage III and IV-A is proposed to better define prognosis.Keywords
This publication has 28 references indexed in Scilit:
- Surgical Treatment in Proximal Bile Duct CancerAnnals of Surgery, 1996
- CholangiocarcinomaAnnals of Surgery, 1996
- Factors Influencing Postoperative Morbidity, Mortality, and Survival After Resection for Hilar CholangiocarcinomaAnnals of Surgery, 1996
- Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinomaSurgery, 1995
- Combined liver transplantation and pancreatoduodenectomy for irresectable hilar bile duct carcinomaBritish Journal of Surgery, 1995
- Major hepatectomy and pancreatoduodenectomy for advanced carcinoma of the biliary tractBritish Journal of Surgery, 1994
- Management Strategies in Resection for Hilar CholangiocarcinomaAnnals of Surgery, 1992
- Abdominal Organ Cluster Transplantation for the Treatment of Upper Abdominal MalignanciesAnnals of Surgery, 1989
- The Role of Liver Transplantation in Hepatobiliary Malignancy. A Retrospective Analysis of 95 Patients with Particular Regard to Tumor Stage and RecurrenceAnnals of Surgery, 1989
- Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatisThe American Journal of Medicine, 1965